Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Alvocidib in R/R AML
NCT03441555Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2018
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of alvocidib in acute myeloid leukemia (AML), sponsored by AbbVie Inc. Primary endpoints: Time to Maximum Plasma Concentration (Tmax) of Venetoclax at 32 days, Clearance of Alvocidib at 32 days and 7 more. Started May 2018; status: completed.
02
Drugs
alvocidib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03441555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03441555.